- Imugene (IMU) has secured a $5.7 million option underwriting agreement with Bell Potter
- The agreement between the company and financial firm relates to the balance of the options not exercised prior to November 30, 2020
- There are over 217 million options available, at an exercise price of 2.6 cents each
- Imugene said the agreement will strengthen its cash reserves, which totalled over $30 million at the end of the June quarter
- The company also said it will use the funds to progress its clinical programs and for IP and milestone payments
- Shares in Imugene are trading down four per cent, for 4.8 cents per share